Safety and efficacy of sitagliptin therapy for the inpatient management of generalmedicine and surgery patients with type 2 diabetes: A pilot, randomized, controlled study

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3430-3435

  Umpierrez, Guillermo E ^a   Gianchandani, Roma ^b   Smiley, Dawn ^a   Jacobs, Sol ^a   Wesorick, David H ^b   Newton, Christopher ^a   Farrokhi, Farnoosh ^a   Peng, Limin ^c   Reyes, David ^a   Lathkar Pradhan, Sangeeta ^b   Pasquel, Francisco ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL SURGERY; ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTICE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART SURGERY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INTENSIVE CARE; LOW DRUG DOSE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SURGICAL TECHNIQUE; THORAX SURGERY; TREATMENT FAILURE; UROLOGIC SURGERY; VERY ELDERLY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INPATIENTS; INSULIN; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PYRAZINES; TRIAZOLES;

EID: 84891854320     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0277     Document Type: Article

References (27)

1. Clement S, Braithwaite SS, Magee MF, et al.; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27: 553-591
2. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978-982
3. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med 2006;355:1903-1911
4. Frisch A, Chandra P, Smiley D, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care 2010; 33:1783-1788
5. Pomposelli JJ, Baxter JK 3rd, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr 1998;22:77-81
6. Noordzij PG, Boersma E, Schreiner F, et al. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. Eur J Endocrinol 2007;156:137-142
7. Moghissi ES, Korytkowski MT, DiNardo M, et al.; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119-1131
8. Schnipper JL, Magee M, Larsen K, Inzucchi SE, Maynard G; Society of Hospital Medicine Glycemic Control Task Force. Society of Hospital Medicine Glycemic Control Task Force summary: practical recommendations for assessing the impact of glycemic control efforts. J Hosp Med 2008;3(Suppl.):66-75
9. Seley JJ, D'Hondt N, Longo R, et al. Position statement: inpatient glycemic control. Diabetes Educ 2009;35:65-69
10. Umpierrez GE, Hellman R, Korytkowski MT, et al.; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97: 16-38
11. Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181-2186
12. Umpierrez GE, Hor T, Smiley D, et al. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:564-569
13. Korytkowski MT, Salata RJ, Koerbel GL, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial.DiabetesCare 2009; 32:594-596
14. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256-261
15. Wexler DJ, Meigs JB, Cagliero E, Nathan DM, Grant RW. Prevalence of hyper-and hypoglycemia among inpatients with diabetes: a national survey of 44 U.S. hospitals. Diabetes Care 2007;30:367-369
16. Boucai L, Southern WN, Zonszein J. Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. Am J Med 2011;124:1028-1035
17. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998;31:950-956
18. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-263
19. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269
20. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-742
21. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30:1979-1987
22. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23:1329-1339
23. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-2571
24. Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006;29:2739-2748
25. Umpierrez GE, Smiley D, Hermayer K, et al. Randomized study comparing a basal bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: Basal Plus Trial. Diabetes Care 22 February 2013 [Epub ahead of print]
26. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 2007;35: 2262-2267
27. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009;32: 1153-1157